Duality Advisers LP Invests $426,000 in Haemonetics Co. (NYSE:HAE)

Posted by on May 8th, 2023

Duality Advisers LP purchased a new position in shares of Haemonetics Co. (NYSE:HAE – Get Rating) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 5,415 shares of the medical instruments supplier’s stock, valued at approximately $426,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of HAE. Wipfli Financial Advisors LLC acquired a new stake in Haemonetics in the third quarter valued at $25,000. Romano Brothers AND Company acquired a new stake in Haemonetics in the fourth quarter valued at $31,000. Eagle Bay Advisors LLC grew its holdings in Haemonetics by 23.6% in the fourth quarter. Eagle Bay Advisors LLC now owns 792 shares of the medical instruments supplier’s stock valued at $62,000 after purchasing an additional 151 shares during the last quarter. Altshuler Shaham Ltd acquired a new stake in Haemonetics in the third quarter valued at $59,000. Finally, Financial Gravity Asset Management Inc. acquired a new stake in Haemonetics in the third quarter valued at $2,248,000.

Haemonetics Stock Performance

Haemonetics stock opened at $82.25 on Monday. The stock’s 50-day moving average is $80.77 and its 200-day moving average is $81.57. The company has a market cap of $4.15 billion, a price-to-earnings ratio of 44.46, a price-to-earnings-growth ratio of 2.50 and a beta of 0.44. The company has a debt-to-equity ratio of 0.98, a current ratio of 3.11 and a quick ratio of 1.99. Haemonetics Co. has a 12 month low of $48.67 and a 12 month high of $91.39.

Haemonetics (NYSE:HAE – Get Rating) last posted its earnings results on Tuesday, February 7th. The medical instruments supplier reported $0.85 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.79 by $0.06. Haemonetics had a return on equity of 19.84% and a net margin of 8.48%. The business had revenue of $305.30 million during the quarter, compared to analyst estimates of $300.47 million. During the same quarter last year, the firm earned $0.84 earnings per share. The company’s revenue for the quarter was up 17.5% compared to the same quarter last year. Equities analysts anticipate that Haemonetics Co. will post 2.94 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on HAE. Mizuho upped their price objective on Haemonetics from $110.00 to $115.00 and gave the company a “buy” rating in a research report on Wednesday, February 8th. Barrington Research upped their price objective on Haemonetics from $94.00 to $103.00 and gave the company an “outperform” rating in a research report on Wednesday, February 8th. StockNews.com began coverage on Haemonetics in a research report on Thursday, March 16th. They issued a “buy” rating on the stock. Morgan Stanley increased their target price on Haemonetics from $84.00 to $88.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 8th. Finally, Citigroup reduced their target price on Haemonetics from $95.00 to $90.00 in a research report on Monday, April 3rd. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, Haemonetics presently has a consensus rating of “Moderate Buy” and an average target price of $100.17.

Haemonetics Company Profile

(Get Rating)

Haemonetics Corp. is a global healthcare company, which engages in the development and distribution of hematology products and solutions. It operates through the following segments: Plasma, Blood Center, Hospital, and Corporate. The Plasma segment offers automated plasma collection and donor management software systems.

Further Reading

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Co. (NYSE:HAE – Get Rating).

Institutional Ownership by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.